bioAffinity Technologies, Inc. announced on June 26, 2025, that its scientists presented breakthrough cancer research at the 2025 RNA Therapeutics Conference. The presentation, titled 'Silencing CD320 and LRP2 by siRNAs selectively kills cancer cells: mechanistic enigmas,' highlighted a novel therapeutic approach.
The research focuses on using small interfering RNAs (siRNAs) to selectively kill cancer cells by targeting two specific cell surface receptors, CD320 and LRP2. Data presented demonstrated that dual suppression of these proteins is highly effective in killing cancer cells across multiple tumor types while sparing normal cells.
This therapeutic approach is the subject of the company’s recently issued U.S. Patent No. 12,305,171 and a patent grant notification from China. Research is currently underway to develop a topical treatment for cutaneous malignancies and neoplasms of the skin, positioning the company favorably in the rapidly expanding market for RNA-based cancer therapeutics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.